Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3807-3810

  Santucci, R ^a   Levêque, Dominique ^a   Lescoute, A ^a   Kemmel, V ^a   Herbrecht, R ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

ABCG2; BCRP; Drug drug interaction; Methotrexate; Proton pump inhibitor

Indexed keywords

ESOMEPRAZOLE; LANSOPRAZOLE; METHOTREXATE; OMEPRAZOLE; PANTOPRAZOLE; ANTINEOPLASTIC AGENT; PROTON PUMP INHIBITOR;

ACUTE KIDNEY FAILURE; ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; BACTERIAL INFECTION; CHOLESTASIS; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INTERACTION; DRUG MEGADOSE; FEMALE; HEART ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYCOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; TUMOR LYSIS SYNDROME; METABOLISM; MIDDLE AGED; NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; METHOTREXATE; MIDDLE AGED; NEOPLASMS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77958570939     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Messmann RA and Allegra CJ: Antifolates. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (eds.). Philadelphia, Lippincott Williams & Wilkins, pp. 139-184, 2001.
2. Aherne GW, Piall E, Marks V, Mould G and White WF: Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1: 1097-1099, 1978.
3. Thyss A, Milano G, Kubar J, Namer M and Schneider M: Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256-258, 1986. (Pubitemid 16132863)
4. Ferrazzini G, Klein J, Sulh H, Chung D, Griesbrecht E and Koren G: Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 117: 823-826, 1990.
5. Blum R, Seymour JF and Toner G: Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann Oncol 13: 327-330, 2002.
6. Dalle J-H, Auvrignon A, Vassal G and Leverger G: Interaction between methotrexate and ciprofloxacin. J Pediatr Hematol Oncol 24: 321-322, 2002.
7. Titier K, Lagrange F, Péhourcq F, Moore N and Molimard M: Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther Drug Monit 24: 570-572, 2002. (Pubitemid 34857914)
8. Zarychanski R, Wlodarczyk K, Ariano R and Bow E: Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentration of methotrexate. J Antimicrob Chemother 58: 228-230, 2006. (Pubitemid 44295021)
9. Sathi N and Dawson J: Methotrexate-induced pancytopenia associated with co-prescription of penicillin and trimethoprim. Clin Rheumatol 26: 134-135, 2007.
10. Takeda M, Khamdang S, Narikawa S, Kimura H, Hosoyamada M, Cha SH, Sekine T and Endou H: Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J Pharmacol Exp Ther 302: 666-671, 2002.
11. Nozaki Y, Kusuhara H, Kondo T, Iwaki M, Shiroyanagi Y, Nakayama H, Horita S, Nakazawa H, Okano T and Sugiyama Y: Species differences in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney cells. J Pharmacol Exp Ther 322: 1162-1170, 2007.
12. Reid T, Yuen A, Catolico M and Carlson RW: Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother Pharmacol 33: 82-84, 1993. (Pubitemid 23336506)
13. Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L and Giraldez J: Potential interaction between methotrexate and omeprazole. Ann Pharmacother 34: 1024-1027, 2000.
14. Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H and Meyer FP: Drug points: Severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br Med J 324: 1497, 2002.
15. Joerger M, Huitema ADR, Van den Bongard HJGD, Baas P, Schornagel JH, Schellens JHM and Beijnen JH: Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 62: 71-80, 2005. (Pubitemid 44195244)
16. Bauters TGM, Verlooy J, Robays H and Laureys G: Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sci 30: 316-318, 2008.
17. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y and Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol 67: 44-49, 2009.
18. Santucci R, Levêque D, Kemmel V, Lutz P, Gérout AC, N'Guyen A, Lescoute A, Schneider F, Bergerat JP and Herbrecht R: Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res 30: 963-965, 2010.
19. Breedveld P, Zelcer N, Pluim D, Sönmezer Ö, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P and Schellens JHM: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 64: 5804-5811, 2004. (Pubitemid 39095580)
20. Huls M, Brown CDA, Windass AS, Sayer R, van den Heuvel JJMW, Heemskerk S, Russel FGM and Masereeuw R: The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 73: 220-225, 2008.
21. Widemann BC and Adamson PC: Understanding and managing methotrexate nephrotoxicity. Oncologist 11: 694-703, 2006.